Introduction
subcutaneous IFN (Interferon Alpha-n1 Wellferon) in accordance with the MRC CML 4 trial protocol. Interferon (IFN) has an established place in the treatFollowing 12 weeks of IFN therapy she presented with severe digital ischaemia of both hands and ment of chronic myeloid leukaemia (CML) achieving a haematological response in 60-80% of patients and distressing throbbing pain necessitating 400 mg morphine sulphate daily. The tips of the digits were nonsignificantly longer survival than that following conventional chemotherapy alone.
1 Adverse effects, often viable, ulcerated and infected (Fig. 1A) . Upper limb pulses were all palpable. Autoimmune (including dose dependent, include a self-limiting flu-like illness, thyroid dysfunction, lupus-like syndrome and Ray-anti-ds DNA, cryoglobulins), coagulation and thrombophilia screens were all negative or within normal naud's phenomenon.
A patient with CML who sustained severe digital range. Subclavian angiography revealed uneven obstruction of the digital arteries (Fig. 1B) . ischaemia of both hands attributable to IFN therapy and who benefited from ketanserin therapy is reported.
Intravenous ketanserin was commenced and 48 h later dextran 40, enoxaparin and aspirin added; cephaclor was started to counter infection and hydroxyurea continued. Within 3 weeks of intravenous Case Summary ketanserin therapy, flow to the digits assessed by Doppler had reverted to normal, the fingers began to A 27-year-old female with no cardiovascular risk fac-heal, and her analgesic requirements decreased. A tors was referred with advanced digital ischaemia of month later debridement resulted in excellent preboth hands. She originally presented with a profound servation of the finger tips. She underwent successful normocytic normochromic anaemia (Hb 6.2 g/dl), bone marrow transplantation and remained on oral marked thrombocytosis (platelets 2273×10 9 /l) with ketanserin 40 mg bd for 6 months after discharge. platelet anisocytosis, giant platelets and occasional blasts. Bone marrow aspiration, trephine biopsy and bone marrow cyogenetics confirmed Philadelphia chromosome positive CML (BCR/ABL fusion gene Discussion detected by RT PCR). Treatment with hydroxyurea was initiated to control the platelet count and subsequently Raynaud's phenomenon, a known side effect of IFN therapy, 2 represents either an exacerbation of preexisting autoimmune disease or a direct unknown * Please address all correspondence to: A. Sachithanandan, Division vasospastic effect. Arteriographically documented dig- . Necrotising vasculitic skin formation of platelet aggregates and induce vasoconstriction. 4 The platelet plug and damaged endoreactions occurring in CML patients on IFN are independent of IFN type, administration modality, dur-thelium release vasoactive substances which trigger the clotting cascade causing microcirculatory thromation of therapy, stage of disease and cytogenetic response to treatment. shape change and weak reversible platelet aggrega-2 Creutzig A, Freund M. Severe Raynaud's syndrome associated tion.
